latest news from
Regulation D Resources

We are excited to announce that Regulation D Resources client HealthySole, Inc. has obtained qualification on their Reg A+ offering! It was a pleasure working with the HealthySole team and thank you for trusting the team at Regulation D Resources for your Reg A+ offering preparation and SEC filing work!

Congrats to Facible Biodiagnostics on your qualified Reg A+ offering and thank you for trusting the team at Regulation D Resources for your Reg A+ offering preparation and SEC filing work!

For Immediate Release

Medical 21, Inc. Engages Regulation D Resources for Regulation A+ Offering Filing Preparation

June 27, 2022

Regulation D Resources Enterprises, Inc.

1536 Cole Blvd., Suite 220

Lakewood, Colorado 80401

(720) 586-8610

Regulation D Resources (“RDR”) is proud to announce that Medical 21, Inc. engaged RDR to prepare a Regulation A+ Tier 2 securities offering. The offering is being prepared and executed in conjunction with Medical Funding Professionals (“MFP”) (www.medicalfundingpro.com), Life Science Intelligence (“LSI”) (www.lifesciencemarketresearch.com) and the Med Tech funding eco-system that MFP and LSI have created.

Manny Villafaña, Ph.D.Sc., named the Living Legend of Medicine, has dedicated the last 50 years of his career to founding companies that develop and deliver successful medtech innovations to the healthcare market. His substantial and lasting contributions to the industry have been responsible for the advancement of cardiac medical devices time and time again. 

Dr. Villafaña is the Founder and CEO of Medical 21 — a company developing a functional artificial artery for cardiac bypass surgery. A groundbreaking graft like theirs would eliminate the need for blood vessel harvesting in cardiac bypass surgery patients, which would reduce complications, pain, costs, and time spent in surgery and recovery. With 7 IPOs under his belt, Medical 21 is Manny’s eighth medical device company — and the most exciting one yet.

“We are extremely excited to have Medical 21, Inc and Dr. Manny Villafaña as clients of RDR and working with this fantastic team at Medical Funding Professionals and Life Science Intelligence. I’m very proud of the team at RDR performing for this client with a 90 day filing preparation timeframe and four day “no comment” turnaround on the SEC submitted filing. Medical 21 is positioned for success and we are grateful to have played a part in assisting them with the preparation and SEC qualification of their Tier 2 Regulation A+ offering”, said Regulation D Resources President Douglas Ruark.

______________________________________________________________________________

About Medical 21, Inc.

15070 23rd Ave North, Minneapolis, MN 55447

info@medical21.com

Medical 21 is a developmental stage medical technology company that is revolutionizing heart bypass surgery with an artificial graft called MAVERICS. Founded by Manny Villafaña, Ph.D.Sc., a “Living Legend of Medicine,” our company has developed a graft that allows the heart bypass procedure to be done without harvesting vessels from the body. Medical 21’s Regulation A offering and circular may be accessed here:  www.investinmanny.com

About Medical Funding Professionals

Medical Funding Professionals is a registered investment advisor firm providing capital and cash flow planning solutions to the medical industry, including life sciences, biotech, medtech, and pharmaceutical sectors. Their Capital Planning Valuation Strategy™ (CPVS) ensures founders and key executives maintain control of their companies as they raise capital and grow. Medical Funding Professionals compliments its advisory services by providing further guidance on how to utilize the updated private company exemptions such as 506c for accredited investors and Reg A+ which allows a company to raise up to $75M from both accredited and non-accredited every 12 months.

http://www.medicalfundingpro.com

About Life Science Intelligence

LSI is a medical technology-focused market intelligence & consulting company that helps medtech executives make informed strategic decisions by better understanding market dynamics, trends, opportunities and the competitive landscape.

https://www.lifesciencemarketresearch.com

About Regulation D Resources Enterprises, Inc.

1536 Cole Blvd., Suite 220, Lakewood, CO 80401

www.regdresources.com

(720) 586-8610

Regulation D Resources (“RDR”) was formed in 1999 to provide Private Placement Offering preparation, SEC Filing preparation, and offering execution support services to entrepreneurs and growing private companies.

Headquartered in Lakewood, Colorado, RDR is one of the leading Regulation D, Regulation CF and Regulation A+ SEC filing service providers in the United States with a comprehensive matrix of services that spans transaction structuring, offering preparation, quarterbacking the offering preparation process, assistance with SEC and State securities filings, and access to the capital markets through RDR’s broker-dealer relationships and FINRA broker-dealer resources.

Regulation A+ Disclaimer

This communication may be deemed to be a solicitation of interest under Regulation A under the Securities Act of 1933, in which case the following apply:

• No money or other consideration is being solicited, and if sent in response, will not be accepted;
• No offer to buy the securities can be accepted and no part of the purchase price can be received until the offering statement is qualified, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of its acceptance given after the qualification date;
• A person’s indication of interest involves no obligation or commitment of any kind; and 
• An offering statement, which would include a preliminary offering circular, has not yet been filed with the SEC.

We are excited to have two featured speakers in the upcoming KoreSummit for raising funding for Medical Technology companies: Douglas Ruark, President and Nicholas Antaki, General Counsel of Regulation D Resources.

Regulation A+ is quickly becoming the default choice for medical technology companies seeking to raise funding. Join us and other industry leaders for the KoreConx summit on funding options for the Med Tech industry.

Regulation D Resources President Douglas Ruark sat down with Jason Fishman of Digital Niche Agency recently to discuss Regulation A+, Regulation CF and the marketing of these offerings to potential investors. If you are seeking to raise funding from investors – watch this podcast for some insight on how these offerings are promoted to the public.

Exciting news! V3 of our critically acclaimed Investor Web Portal Software system is launching March 2022. Stay tuned for updates on the system enhancements and user features added to help you manage your Reg D, CF or A+ offering more effectively!

Our offices will be closed Monday, Feb. 21, 2022 in observance of Presidents Day. We will re-open at 9am MST Tuesday on our normal hours.

We will be closed on Monday, January 17th, 2022 in observance of the Martin Luther King holiday. We will re-open Tuesday, January 18th at 9am MST.

Merry Christmas and Happy New Year Everyone!

Our offices will be closed Wed., December 22nd at 1pm MST through Friday, December 24th.  We will re-open at 9am MST Monday, December 27th.

For the New Year Holiday – our offices will be closed December 31st.

We hope everyone has a safe and happy holiday season!

 

 

 

Please note we will be instituting an amended fee schedule for the following services effective on 2pm MST on Friday, November 26th, 2021:

– Regulation CF Offering Preparation Services Fee:  total fee of $10,000.00 paid $5,000 as an engagement fee and the balance due 30 days net.

– Regulation D Offering Preparation Services Fee: total fee of $8,000.00 paid $5,000 as an engagement fee and the balance due 30 days net.

Interested in preparing a Regulation D or CF offering?  Call us today to discuss!  (720) 586-8610.